Brought to you by 
Transition Therapeutics and Lilly's newest deal focuses on osteoarthritis
03 Feb 2023
Executive Summary
Transition Therapeutics Inc. (treatments for CNS, metabolic, and musculoskeletal conditions) has once again expanded its relationship with partner Eli Lilly & Co., this time getting exclusive rights to the Big Pharma’s preclinical osteoarthritis candidate TT601.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Transition Therapeutics and Lilly's newest deal focuses on osteoarthritis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice